Changeflow GovPing Pharma & Drug Safety Anti-Giardial Heterocyclic Compounds for Parasi...
Routine Notice Added Final

Anti-Giardial Heterocyclic Compounds for Parasitic Infections

Favicon for changeflow.com USPTO Patent Applications - Organic Chemistry (C07D)
Published
Detected
Email

Summary

USPTO published patent application US20260098047A1 covering heterocyclic compounds of Formula (I) and (II) for treatment and prevention of Giardiasis (parasitic infection). The application names four inventors and includes pharmaceutical composition claims and methods of using the compounds.

What changed

USPTO published patent application US20260098047A1 for anti-Giardial heterocyclic compounds classified under C07D (organic chemistry). The application covers compounds of Formula (I) and Formula (II), their salts, solvates, and stereoisomers, along with pharmaceutical compositions and methods for preventing and treating Giardiasis.

Pharmaceutical companies and biotechnology firms developing antiparasitic drugs should monitor this application for potential licensing opportunities. The broad patent claims covering multiple heterocyclic compound families and therapeutic uses may impact freedom-to-operate assessments for competing Giardiasis treatments.

What to do next

  1. Monitor patent database for grant status
  2. Evaluate licensing opportunities for Giardiasis therapeutics
  3. Review compound claims for R&D alignment

Archived snapshot

Apr 10, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

Anti-Giardial Compounds

Application US20260098047A1 Kind: A1 Apr 09, 2026

Inventors

Tina Sherrie Adams, Christopher John Saville Hart, John Henry Ryan, Andrew Geoffrey Riches

Abstract

The present disclosure relates to compounds that find application as therapeutics. In particular, the disclosure relates to compounds of Formula (I) or Formula (II) and their pharmaceutically acceptable salt, solvates, or stereoisomers thereof, to pharmaceutical compositions containing such compounds, to methods for using such compounds in the prevention and/or treatment of Giardiasis, and to related uses.

CPC Classifications

C07D 519/00 A61K 31/407 A61K 31/4155 A61K 31/427 A61K 31/429 A61K 31/454 A61K 31/496 A61K 31/5355 A61K 31/5377 A61K 31/538 A61K 31/541 A61K 31/553 A61P 33/02 C07D 413/06 C07D 471/04 C07D 487/04 C07D 495/04 C07D 498/04 C07D 513/04

Filing Date

2023-07-14

Application No.

18994567

View original document →

Get daily alerts for USPTO Patent Applications - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 9th, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US20260098047A1

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers Clinical investigators
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent filing Drug compound research Therapeutic development
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Public Health

Get alerts for this source

We'll email you when USPTO Patent Applications - Organic Chemistry (C07D) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!